Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/334"
Predicate | Value (sorted: default) |
rdfs:label |
|
rdf:type |
|
?:Evidence_enzyme_system |
|
?:Evidence_type |
|
?:content |
"route of administration: oral
study duration: "In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the final duloxetine dose. On the final day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. "
population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study
tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.
ages: 21 - 27
description:
"Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.""
|
dc:creator |
|
dc:date |
|
rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ duloxetine_is_not_substrate_of_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1371 }
Context graph